## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 11, 2023

## ANEBULO PHARMACEUTICALS, INC

(Exact name of registrant as specified in its charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-40388 (Commission File Number) 85-1170950 (IRS Employer Identification No.)

1415 Ranch Road 620 South, Suite 201 Lakeway, TX (Address of Principal Executive Offices)

78734 (Zip Code)

Registrant's telephone number, including area code: (512) 598-0931

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	ANEB	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  $\boxtimes$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 8.01 Other Events.

On March 28, 2023, Anebulo Pharmaceuticals, Inc. filed a Current Report on Form 8-K (the "March 8-K") that included results from iterandomized, double-blind, placebocontrolled Phase 2 clinical trial evaluating ANEB-001 as a potential treatment for ACI in healthy volunteers challenged with oral delta-9-tetrahydrocannabinol. The charts contained in Exhibit 99.1 to this Current Report on Form 8-K are incorporated by reference herein and graphically present data that is consistent with the data reported in the March 8-K.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit	
Number	Description
99.1	Part B Final Data Charts
104	Cover Page of Interactive Data File (embedded within the Inline XBRL document).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### ANEBULO PHARMACEUTICALS, INC.

Date: April 11, 2023

By: /s/ Simon Allen Simon Allen


Chief Executive Officer

1


# Part B Final Data: Effect of Delayed Dosing on Feeling High

Time Course of VAS Feeling High – Delayed Dosing of ANEB-001 at 1 hr after THC

### Pooled Cohorts (3 and 5) - 21 mg or 30 mg THC and 10 mg ANEB-001/PBO



## Part B Final Data: Effect of Delayed Dosing on Alertness






ANEBULO

# Part B Final Data: Effect of Delayed Dosing on Body Sway



Pooled Cohorts (3 and 5) - 21 mg or 30 mg THC and 10 mg ANEB-001/PBO






3

4

# Part B Final Data: Effect of Delayed Dosing on Heart Rate



ANEBULO

ANEBULO

Data are Mean (SD) 🛛 👆 THC Dosed 👆 ANEB-001/PBO Dosed